Legal & General Group
WHWK

Legal & General Group’s Whitehawk Therapeutics WHWK Stock Holding History

Legal & General Group’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,484
Closed -$3.47K – 3526
2024
Q1 		$3.47K Hold
1,484
– – ﹤0.01% 3322
2023
Q4 		$3K Hold
1,484
– – ﹤0.01% 3349
2023
Q3 		$7.18K Hold
1,484
– – ﹤0.01% 3327
2023
Q2 		$10.2K Sell
1,484
-341
-19% -$2.65K ﹤0.01% 3319
2023
Q1 		$13.2K Hold
1,825
– – ﹤0.01% 3158
2022
Q4 		$23.4K Buy
1,825
+267
+17% +$3.49K ﹤0.01% 3118
2022
Q3 		$22K Sell
1,558
-1,217
-44% -$16K ﹤0.01% 3186
2022
Q2 		$34K Buy
+2,775
New +$41.2K ﹤0.01% 3086

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Legal & General Group's WHWK Position: Q2 2024 in Review

Legal & General Group sold out of Whitehawk Therapeutics (WHWK) in Q2 2024, closing a stake of 1,484 shares — an estimated $3.47K sold.

Legal & General Group first reported a position in WHWK in Q2 2022 and held it in 8 quarters. The position peaked at $34K in Q2 2022. 65 funds tracked by Wall St. Rank hold WHWK as of Q2 2024.

  • Legal & General Group reported no remaining Whitehawk Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Legal & General Group sold 1,484 Whitehawk Therapeutics shares in Q2 2024, an estimated $3.47K.
  • Legal & General Group first reported a position in Whitehawk Therapeutics in Q2 2022 and held it in 8 quarters.
  • Legal & General Group's Whitehawk Therapeutics position peaked at $34K in Q2 2022.
  • 65 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2024.

Based on Legal & General Group's 13F filing for Q2 2024, filed 14 Aug 2024.